Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Common Equity (2016 - 2025)

Historic Common Equity for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $137.4 million.

  • Gyre Therapeutics' Common Equity rose 3954.44% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year increase of 3954.44%. This contributed to the annual value of $98.4 million for FY2024, which is 72169.57% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Common Equity stood at $137.4 million, which was up 3954.44% from $129.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Common Equity ranged from a high of $137.4 million in Q3 2025 and a low of -$28.3 million during Q2 2023
  • Over the past 5 years, Gyre Therapeutics' median Common Equity value was $79.1 million (recorded in 2022), while the average stood at $62.2 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Common Equity tumbled by 19582.41% in 2023, and later skyrocketed by 269994.31% in 2024.
  • Gyre Therapeutics' Common Equity (Quarter) stood at $41.1 million in 2021, then skyrocketed by 75.76% to $72.2 million in 2022, then tumbled by 121.92% to -$15.8 million in 2023, then surged by 721.7% to $98.4 million in 2024, then soared by 39.65% to $137.4 million in 2025.
  • Its Common Equity was $137.4 million in Q3 2025, compared to $129.4 million in Q2 2025 and $104.3 million in Q1 2025.